The Brain-Wave Trial That Just Raised the Bar for Neuromodulation RCTs
A double-blind tACS trial targeting theta oscillations in methamphetamine patients sets a new design standard regulators will use to...
FDA Regulatory Strategy
FDA’s 2026 Single-Trial Default Standard Reframes the Dual-Pivotal Debate for Sponsors Still Designing Phase 3
FDA's 2026 shift to a single pivotal trial as the default approval standard forces sponsors to rethink Phase 3...
The Validation Accords: Clinical Trials Are About to Learn What “Validated AI” Actually Means
Nature Medicine's Validation Accords push for a generative AI consensus framework, and expose a regulatory gap that could invalidate...
The Clinical Trial That Asks Whether Your Current Treatment Should Exist
JAMA's deescalation trial framework forces a reckoning: 22% of prescriptions are unnecessary, and regulators have no standard playbook for...
Latigo’s LTG-001 Phase 2b Data Signals a New Design Standard for NaV1.8 Pain Trials
Latigo Biotherapeutics' LTG-001 hit SPID48 in 343 patients, published in NEJM — here's what the trial design tells regulators...
A Maternal GBS Vaccine Just Cleared Phase 1/2. Here’s What the Trial Design Tells Us About the Regulatory Gauntlet Ahead.
Pfizer's 6-valent GBS vaccine cleared Phase 1/2 with strong immunogenicity data in pregnant women. Here's what the trial design...
The Hybrid Vaccine Trial Design That Could Render Pure RCTs Obsolete
A landmark NEJM editorial argues combining RCT and observational data can unlock vaccine effectiveness insights no single design can...
Digital Twins Are Rewriting Clinical Trial Math. The Validation Problem Could Erase the Gains.
Biotech's digital twin rush is outpacing regulatory frameworks. Without standardized qualification, sponsors risk building trial strategies on unvalidated…
FDA’s Single-Trial Default: What It Actually Means for Your Protocol Strategy
FDA made a single pivotal trial its default approval standard on Feb. 19, 2026. Here's what clinical ops leaders...
The Geroscience Biomarker Gap: Why Immune Aging Endpoints Are About to Reshape Trial Design
Nature Medicine's immune aging biomarker framework challenges sponsors to redesign geroscience trials around surrogate endpoints the FDA hasn't yet...